BR112015031088A2 - composições e métodos de imunização contra c. difficile - Google Patents

composições e métodos de imunização contra c. difficile

Info

Publication number
BR112015031088A2
BR112015031088A2 BR112015031088A BR112015031088A BR112015031088A2 BR 112015031088 A2 BR112015031088 A2 BR 112015031088A2 BR 112015031088 A BR112015031088 A BR 112015031088A BR 112015031088 A BR112015031088 A BR 112015031088A BR 112015031088 A2 BR112015031088 A2 BR 112015031088A2
Authority
BR
Brazil
Prior art keywords
difficile
toxin
patient
methods against
immunization compositions
Prior art date
Application number
BR112015031088A
Other languages
English (en)
Portuguese (pt)
Inventor
Foglia Ginamarie
De Bruyn Guy
Pietrobon Patricia
Gurunathan Sanjay
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031088(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BR112015031088A2 publication Critical patent/BR112015031088A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112015031088A 2013-06-14 2014-06-13 composições e métodos de imunização contra c. difficile BR112015031088A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
BR112015031088A2 true BR112015031088A2 (pt) 2017-07-25

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031088A BR112015031088A2 (pt) 2013-06-14 2014-06-13 composições e métodos de imunização contra c. difficile

Country Status (12)

Country Link
US (4) US9730994B2 (enExample)
EP (1) EP3007724B1 (enExample)
JP (1) JP6691477B2 (enExample)
KR (1) KR20160020543A (enExample)
CN (1) CN105611942A (enExample)
AU (1) AU2014277981B2 (enExample)
BR (1) BR112015031088A2 (enExample)
CA (1) CA2915279A1 (enExample)
MX (1) MX2015017257A (enExample)
SG (1) SG11201510166YA (enExample)
TW (1) TWI648063B (enExample)
WO (1) WO2014201346A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
IL320444A (en) * 2017-09-28 2025-06-01 Pfizer Compositions and methods for stimulating an immune response against Clostridium difficile

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CN101855336B (zh) * 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JP2016516721A (ja) 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
BR112015023469A8 (pt) * 2013-03-15 2019-12-03 Sanofi Pasteur Inc toxóides, composições e métodos relacionados
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile

Also Published As

Publication number Publication date
TWI648063B (zh) 2019-01-21
MX2015017257A (es) 2016-11-11
SG11201510166YA (en) 2016-01-28
CA2915279A1 (en) 2014-12-18
JP6691477B2 (ja) 2020-04-28
US9730994B2 (en) 2017-08-15
EP3007724A1 (en) 2016-04-20
EP3007724B1 (en) 2023-07-05
US20200113991A1 (en) 2020-04-16
AU2014277981B2 (en) 2019-06-20
US20170304423A1 (en) 2017-10-26
US20160120968A1 (en) 2016-05-05
CN105611942A (zh) 2016-05-25
US20210145956A1 (en) 2021-05-20
US11419930B2 (en) 2022-08-23
JP2016521754A (ja) 2016-07-25
WO2014201346A1 (en) 2014-12-18
TW201536314A (zh) 2015-10-01
KR20160020543A (ko) 2016-02-23
AU2014277981A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
BR112015031088A2 (pt) composições e métodos de imunização contra c. difficile
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
BR112017001796A2 (pt) composições de flagelina e seus usos
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
EA201691443A1 (ru) Накожное восстановление иммунобаланса
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
MX2022011167A (es) Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
BR112017014343A2 (pt) composição contendo quitina e proteínas digeríveis
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
BR112016028227A2 (pt) método para redução de imunogenicidade de proteína e peptídeo
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
EA201790958A1 (ru) Сублингвальный препарат рилузола
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
PH12016500766A1 (en) Age-tailored nutritional compositions with a varying protein content
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]